DOP2002000545A - Moléculas pequeñas para el tratamiento del crecimiento celular anormal - Google Patents

Moléculas pequeñas para el tratamiento del crecimiento celular anormal

Info

Publication number
DOP2002000545A
DOP2002000545A DO2002000545A DO2002000545A DOP2002000545A DO P2002000545 A DOP2002000545 A DO P2002000545A DO 2002000545 A DO2002000545 A DO 2002000545A DO 2002000545 A DO2002000545 A DO 2002000545A DO P2002000545 A DOP2002000545 A DO P2002000545A
Authority
DO
Dominican Republic
Prior art keywords
small molecules
treatment
cell growth
abnormal cell
relates
Prior art date
Application number
DO2002000545A
Other languages
English (en)
Inventor
John Charles Kath
James Dale Moyer
Richard Damian Connell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2002000545A publication Critical patent/DOP2002000545A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a moleculas pequenas que son utiles en el tratamiento del crecimiento celular anormal, tal como el cancer, en mamiferos. Esta invencion tambien se refiere a un procedimiento de use de tales moleculas pequenas en el tratamiento del crecimiento celular anormal en mamiferos, especialmente en seres humanos, y a composiciones farmaceuticas que contienen tales compuestos. La invencion se refiere ademas a pequenas moleculas que son selectivas pars el receptor. erbB2 respecto al receptor erbBl, teniendo dicho inhibidor de erbB2 un intervalo de selectividades por erbB2 respecto a erbBl entre 50-1500.
DO2002000545A 2001-12-12 2002-12-10 Moléculas pequeñas para el tratamiento del crecimiento celular anormal DOP2002000545A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
DOP2002000545A true DOP2002000545A (es) 2003-06-16

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000545A DOP2002000545A (es) 2001-12-12 2002-12-10 Moléculas pequeñas para el tratamiento del crecimiento celular anormal

Country Status (29)

Country Link
US (1) US20030171386A1 (es)
EP (1) EP1465632A1 (es)
JP (1) JP4181502B2 (es)
KR (1) KR20040063948A (es)
CN (1) CN1602195A (es)
AP (1) AP2004003058A0 (es)
AR (1) AR037771A1 (es)
AU (1) AU2002339687A1 (es)
BR (1) BR0214499A (es)
CA (1) CA2469670A1 (es)
DO (1) DOP2002000545A (es)
EA (1) EA200400680A1 (es)
EC (1) ECSP045146A (es)
GT (1) GT200200273A (es)
HR (1) HRP20040529A2 (es)
HU (1) HUP0501069A2 (es)
IL (1) IL161908A0 (es)
IS (1) IS7233A (es)
MA (1) MA27154A1 (es)
MX (1) MXPA04004107A (es)
NO (1) NO20042882L (es)
OA (1) OA12734A (es)
PA (1) PA8561301A1 (es)
PE (1) PE20030760A1 (es)
PL (1) PL373848A1 (es)
TN (1) TNSN04111A1 (es)
TW (1) TW200301121A (es)
WO (1) WO2003049740A1 (es)
ZA (1) ZA200404264B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
WO2004054585A1 (en) * 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
CN1838959A (zh) * 2003-08-18 2006-09-27 辉瑞产品公司 Erbb2抗癌剂的给药方案
CA2537812C (en) 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
CN1921864A (zh) * 2003-12-24 2007-02-28 西奥斯公司 使用TGF－β抑制剂治疗神经胶质瘤
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
PL2245026T3 (pl) 2008-02-07 2013-01-31 Boehringer Ingelheim Int Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
WO2009113560A1 (ja) 2008-03-12 2009-09-17 武田薬品工業株式会社 縮合複素環化合物
ES2444128T3 (es) 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CA3099440A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
JP2023512174A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP2023512175A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
WO2001004111A1 (en) * 1999-07-09 2001-01-18 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
EE05107B1 (et) * 1999-10-19 2008-12-15 Merck & Co., Inc. Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
UA75482C2 (en) * 2001-12-12 2006-04-17 Pfizer Prod Inc Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer

Also Published As

Publication number Publication date
MXPA04004107A (es) 2004-07-23
PA8561301A1 (es) 2003-12-30
CN1602195A (zh) 2005-03-30
HRP20040529A2 (en) 2004-10-31
GT200200273A (es) 2003-10-03
EP1465632A1 (en) 2004-10-13
PL373848A1 (en) 2005-09-19
PE20030760A1 (es) 2003-09-05
AR037771A1 (es) 2004-12-01
ECSP045146A (es) 2004-07-23
BR0214499A (pt) 2005-05-10
HUP0501069A2 (en) 2006-06-28
TW200301121A (en) 2003-07-01
NO20042882L (no) 2004-07-07
EA200400680A1 (ru) 2005-06-30
JP2005527486A (ja) 2005-09-15
MA27154A1 (fr) 2005-01-03
ZA200404264B (en) 2005-08-31
KR20040063948A (ko) 2004-07-14
OA12734A (en) 2006-06-28
CA2469670A1 (en) 2003-06-19
AP2004003058A0 (en) 2004-06-30
IS7233A (is) 2004-04-26
JP4181502B2 (ja) 2008-11-19
TNSN04111A1 (fr) 2006-06-01
IL161908A0 (en) 2005-11-20
AU2002339687A1 (en) 2003-06-23
US20030171386A1 (en) 2003-09-11
WO2003049740A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
DOP2002000545A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP066406A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
HN2006042221A (es) Derivados de piridina para el tratamiento del crecimiento celular anormal
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
PA8680701A1 (es) Derivados de oxindol
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
HN2001000192A (es) Derivados de pirazol
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
UY28150A1 (es) Agentes terapeuticos
BRPI0514474A (pt) multiparticulados
ECSP045392A (es) Moduladores tetrahidropiranil-ciclopentil-tetrahidropiridopiridinicos de la actividad de receptores de quimiocina
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
CO6331473A2 (es) Derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetilo como antagonistas alfa2c para uso en el tratamiento de enfermedades del sistema nervioso central y periferico
UY28731A1 (es) Compuestos quimicos
GT200500228A (es) Prodroga de benzoxazoles sustituidos como agentes estrogenicos
UY28894A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
ECSP066925A (es) Derivados de piperidina como antagonistas del receptor de quimiocina
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.